FDA Approves New Treatment for Rosacea

The U.S. Food and Drug Administration (FDA) has approved Allergan’s Rhofade cream for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults. The National Rosacea Society (NRS) estimates that approximately 16 million Americans are affected by rosacea, yet effective treatment has been limited.  “Historically, there haven’t been many options available to help physicians address persistent facial erythema and often we ended up just helping our patients identify and manage triggers, which can lead to frustration for both the doctor and patient,” says Robert Weiss, M.D., clinical trial investigator and director of Maryland Laser, Skin & Vein Institute (Baltimore). “With the approval of Rhofade, doctors will now be able to provide their patients with an effective once-daily treatment option to help manage this condition.”

Suggested Articles

Prioritizing your own health in the weeks and months before surgery is essential for proper recovery. Here are a few doctor-recommended tips to get you…

Customer acquisition costs a lot more than customer retention. In fact, according to the Harvard Business Review, depending on what industry you’re in, “…

This week the U.S. Food and Drug Administration (FDA) announced a voluntary global recall of Allergan’s Biocell textured breast implants.